Pfizer Inc. delivered a financial jolt in its third quarter of 2024, surpassing Wall Street’s expectations and raising its annual revenue and earnings guidance for the year. The pharmaceutical giant, known for its blockbuster COVID-19 products, is now forging ahead with a diversified growth strategy, reflecting a well-balanced portfolio of oncology, cardiology, and other in-demand […]
Zydus Lifesciences has bagged final approval from the US Food and Drug Administration (FDA) for Apixaban Tablets, 2.5mg and 5mg, a generic version of Eliquis Tablets. Apixaban inhibits the activity of certain clotting compounds in the blood. It reduces the chance of suffering from stroke or blood clots in patients with a heart rhythm disorder […]
Micro Labs and Mylan Pharmaceuticals have secured approval from the US Food and Drug Administration (FDA) for two applications for the first generics of Eliquis (apixaban) tablets to cut down the risk of stroke and systemic embolism in patients having nonvalvular atrial fibrillation. Apixaban is also indicated for the preventive treatment of deep vein thrombosis […]
Bristol-Myers Squibb has reached a definitive agreement to acquire Celgene Corporation in a monumental cash-and-stock deal worth approximately $74 billion. This acquisition will merge two pharmaceutical giants into a specialty biopharma company focused on cutting-edge therapies for cancer, cardiovascular disease, and immunological conditions. Details of the Bristol-Myers Squibb Celgene merger Under the terms of the […]